Standard BioTools Announces Sale Of Mass Cytometry Business And Illumina’s Buyout Of Contingent Payments To Advance Merger With Treeline Biosciences - LAB News | Rallies
Standard BioTools Announces Sale Of Mass Cytometry Business And Illumina’s Buyout Of Contingent Payments To Advance Merger With Treeline Biosciences L LAB • 2026-07-28 Reuters brief on Standard BioTools transaction
Standard BioTools announces sale of mass cytometry business and Illumina’s buyout of contingent payments to advance merger with Treeline Biosciences
Standard BioTools to sell mass cytometry business to Multiplex Bio
Standard BioTools said the mass cytometry business sale is valued at up to $10 million
•
2026-07-28
LAB•
